CYRX — Cryoport, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1124524 ·
Last close
$17.38
Market Cap
$880.28M
52W High
$17.98
52W Low
$7.61
ADV30
574,913
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 48,971,000 | 22,824,000 | -10,039,000 | -8,255,000 | 756,204,000 | 269,267,000 | 265,505,000 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 45,450,000 | 21,711,000 | -10,031,000 | -11,644,000 | 764,989,000 | 250,494,000 | 262,351,000 |
| Sep 2025 | 44,233,000 | 21,325,000 | -9,932,000 | -6,943,000 | 774,328,000 | 255,811,000 | 261,057,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-503,000
Investing CF
$263,119,000
Financing CF
$-20,800,000
CapEx
$-25,709,000
Dividends Paid
—
Buybacks
$-5,752,000
EPS Diluted TTM
$1.35
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-707,683,000
Inventory
$21,506,000
Receivables
$36,454,000
ST Investments
$127,426,000
EBIT TTM
$-28,890,000
Pretax Income TTM
$-31,000,000
Interest Exp TTM
$2,110,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$186,452,000
EBITDA
$-3,457,000
Free Cash Flow
$-14,678,000
Enterprise Value
$669,193,536
Total Cash
$396,692,992
Total Debt
$232,018,000
Shares Out
50,649,100
Trailing EPS
$-0.82
Book Value
$8.78
ROE
-6.5%
ROA
-2.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 176,177,000 | -36,806,000 | 78,301,000 | 764,989,000 | 262,351,000 | 502,638,000 | -8,580,000 |
| Dec 2024 | 156,769,000 | -57,862,000 | -114,756,000 | 703,492,000 | 301,594,000 | 401,898,000 | -16,323,000 |
| Dec 2023 | 168,662,000 | -50,968,000 | -99,587,000 | 957,744,000 | 468,721,000 | 489,023,000 | -757,000 |
| Dec 2022 | 237,277,000 | -31,904,000 | -37,333,000 | 1,038,746,000 | 482,908,000 | 555,838,000 | -1,851,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.66
Max Pain — expiry 2026-12-18
max pain strike: $15.00 · spot: $17.38 · call oi: 7,979 · put oi: 78Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARDX | ARDELYX, INC. | $880.42M | $3.41 | — |
| TBPH | Theravance Biopharma, Inc. | $884.18M | $17.03 | — |
| ANL | Adlai Nortye Group Ltd. | $904.51M | $15.40 | — |
| JBIO | Jade Biosciences, Inc. | $912.62M | $14.35 | — |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $845.42M | $1.90 | — |
News headlines (Yahoo Finance, 1h cache)
Cryoport (CYRX) Stock Fair Value Rises After Analysts Lift Growth Assumptions
2026-08-24 04:29 · Yahoo
Cryoport (CYRX) Q2 2026 Earnings Call Transcript
2026-08-14 04:28 · Yahoo
CryoPort (CYRX) Upgraded to Buy: Here's Why
2026-08-11 16:00 · Yahoo
CryoPort, Inc. (CYRX) Reports Q2 Loss, Beats Revenue Estimates
2026-08-06 21:40 · Yahoo
Cryoport (CYRX) Stock Fair Value Rises After Analysts Lift Targets On Growth Trends
2026-07-27 05:06 · Yahoo
Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-23 12:00 · Yahoo
Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
2026-06-25 12:00 · Yahoo
Cryoport (CYRX) Stock Fair Value Rises After Analysts Revisit Bioservices Outlook
2026-06-13 12:11 · Yahoo
Cryoport (CYRX) Q1 2026 Earnings Transcript
2026-05-04 22:21 · Yahoo
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
2026-05-04 21:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.